AIM: To study plasma levels of vascular endothelial growth factor (VEGF), endothelin-1(ET-1) and nitric oxide (NO) in patients with proliferative diabetic retinopathy (PDR) before and after pan-retinal photocoagulation (PRP). METHODS: Forty patients (23 females and 17 males, mean age 48.5±12.2 years) with PDR without previous PRP therapy were studied. Blood samples were obtained before and 3 months after the last PRP session. Baseline (prelaser) plasma levels of VEGF, ET-1 and NO were compared with their levels in 30 healthy age- and sex- matched controls and also with plasma levels 3 months post-PRP. RESULTS: Patients with PDR had significantly raised plasma VEGF (375±89ng/L), ET-1(20±5ng/L) and NO (135±53µmol/L) when compared with healthy control group (P<0.01). After PRP, there was a significant reduction in plasma VEGF (179±66ng/L), ET-1 (11±5ng/L) and NO (91±49µmol/L) levels at 3 months' follow-up but still significantly higher than healthy controls. CONCLUSION: Patients with PDR demonstrate elevated VEGF, ET-1 and NO, which decrease after successful laser treatment.
AIM: To study plasma levels of vascular endothelial growth factor (VEGF), endothelin-1(ET-1) and nitric oxide (NO) in patients with proliferative diabetic retinopathy (PDR) before and after pan-retinal photocoagulation (PRP). METHODS: Forty patients (23 females and 17 males, mean age 48.5±12.2 years) with PDR without previous PRP therapy were studied. Blood samples were obtained before and 3 months after the last PRP session. Baseline (prelaser) plasma levels of VEGF, ET-1 and NO were compared with their levels in 30 healthy age- and sex- matched controls and also with plasma levels 3 months post-PRP. RESULTS:Patients with PDR had significantly raised plasma VEGF (375±89ng/L), ET-1(20±5ng/L) and NO (135±53µmol/L) when compared with healthy control group (P<0.01). After PRP, there was a significant reduction in plasma VEGF (179±66ng/L), ET-1 (11±5ng/L) and NO (91±49µmol/L) levels at 3 months' follow-up but still significantly higher than healthy controls. CONCLUSION:Patients with PDR demonstrate elevated VEGF, ET-1 and NO, which decrease after successful laser treatment.
Authors: P A Marsden; H H Heng; S W Scherer; R J Stewart; A V Hall; X M Shi; L C Tsui; K T Schappert Journal: J Biol Chem Date: 1993-08-15 Impact factor: 5.157
Authors: N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller Journal: Lancet Date: 1998-01-03 Impact factor: 79.321
Authors: T Kozawa; H Sone; Y Okuda; Y Kawakami; Y Sekine; M Imai; S Hommura; M Inatomi; S Yaguchi; K Matsuo; T Segawa; H Suzuki; K Yamashita Journal: Nippon Ganka Gakkai Zasshi Date: 1998-11
Authors: Ruth B Caldwell; Manuela Bartoli; M Ali Behzadian; Azza E B El-Remessy; Mohamed Al-Shabrawey; Daniel H Platt; R William Caldwell Journal: Diabetes Metab Res Rev Date: 2003 Nov-Dec Impact factor: 4.876
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245